195 related articles for article (PubMed ID: 33197837)
21. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
Yan M; Bomeisl P; Gilmore H; Harbhajanka A
Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
[TBL] [Abstract][Full Text] [Related]
22. Preoperative clinicopathologic factors and breast magnetic resonance imaging features can predict ductal carcinoma in situ with invasive components.
Lee CW; Wu HK; Lai HW; Wu WP; Chen ST; Chen DR; Chen CJ; Kuo SJ
Eur J Radiol; 2016 Apr; 85(4):780-9. PubMed ID: 26971424
[TBL] [Abstract][Full Text] [Related]
23. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.
Komforti M; Badve SS; Harmon B; Lo Y; Fineberg S
Histopathology; 2020 Nov; 77(5):749-759. PubMed ID: 32557780
[TBL] [Abstract][Full Text] [Related]
24. Upgrade rate of intraductal papilloma without atypia on breast core needle biopsy: A clinical, radiological and pathological correlation study.
Genco IS; Tugertimur B; Manolas PA; Hasanovic A; Hajiyeva S
Am J Surg; 2020 Sep; 220(3):677-681. PubMed ID: 32007236
[TBL] [Abstract][Full Text] [Related]
25. Lobular carcinoma in situ or atypical lobular hyperplasia at core-needle biopsy: is excisional biopsy necessary?
Foster MC; Helvie MA; Gregory NE; Rebner M; Nees AV; Paramagul C
Radiology; 2004 Jun; 231(3):813-9. PubMed ID: 15105449
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.
Kim J; Han W; Lee JW; You JM; Shin HC; Ahn SK; Moon HG; Cho N; Moon WK; Park IA; Noh DY
Breast; 2012 Oct; 21(5):641-5. PubMed ID: 22749854
[TBL] [Abstract][Full Text] [Related]
27. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
28. Surgical follow-up and clinical presentation of 142 breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy.
Rizzo M; Lund MJ; Oprea G; Schniederjan M; Wood WC; Mosunjac M
Ann Surg Oncol; 2008 Apr; 15(4):1040-7. PubMed ID: 18204989
[TBL] [Abstract][Full Text] [Related]
29. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
30. Use of Breast Magnetic Resonance Imaging in Women Diagnosed With Atypical Ductal Hyperplasia at Core Needle Biopsy Helps Select Women for Surgical Excision.
Amitai Y; Menes T; Golan O
Can Assoc Radiol J; 2018 Aug; 69(3):240-247. PubMed ID: 29958833
[TBL] [Abstract][Full Text] [Related]
31. Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.
Chang WC; Hsu HH; Yu JC; Ko KH; Peng YJ; Tung HJ; Chang TH; Hsu GC
Eur J Radiol; 2014 Jun; 83(6):935-941. PubMed ID: 24666513
[TBL] [Abstract][Full Text] [Related]
32. Reducing indications for radial scar surgical excision in Slovenian breast cancer screening program.
Gašljević G; Hertl K; Gazić B; Lamovec J; Žgajnar J
Ann Diagn Pathol; 2020 Apr; 45():151438. PubMed ID: 31927469
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting the under-diagnosis of atypical ductal hyperplasia diagnosed by core needle biopsies - A 10-year retrospective study and review of the literature.
Co M; Kwong A; Shek T
Int J Surg; 2018 Jan; 49():27-31. PubMed ID: 29146271
[TBL] [Abstract][Full Text] [Related]
34. Follow-up of breast papillary lesion on core needle biopsy: experience in African-American population.
Wang H; Tsang P; D'Cruz C; Clarke K
Diagn Pathol; 2014 Apr; 9():86. PubMed ID: 24762090
[TBL] [Abstract][Full Text] [Related]
35. Radiologic and Pathologic Features Associated With Upgrade of Atypical Ductal Hyperplasia at Surgical Excision.
Williams KE; Amin A; Hill J; Walter C; Inciardi M; Gatewood J; Redick M; Wick J; Hunt S; Winblad O
Acad Radiol; 2019 Jul; 26(7):893-899. PubMed ID: 30318287
[TBL] [Abstract][Full Text] [Related]
36. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
37. Is core needle biopsy superior to fine-needle aspiration biopsy in the diagnosis of papillary breast lesions?
Masood S; Loya A; Khalbuss W
Diagn Cytopathol; 2003 Jun; 28(6):329-34. PubMed ID: 12768640
[TBL] [Abstract][Full Text] [Related]
38. Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ.
Nakhlis F; Harrison BT; Giess CS; Lester SC; Hughes KS; Coopey SB; King TA
Ann Surg Oncol; 2019 Jan; 26(1):55-61. PubMed ID: 30362065
[TBL] [Abstract][Full Text] [Related]
39. Upgrade rates and outcomes of screen-detected atypical intraductal epithelial proliferation (AIDEP) diagnosed on core needle biopsy.
Dunne EC; Quinn EM; Stokes M; Barry JM; Kell M; Flanagan F; Kennedy MM; Walsh SM
Breast Dis; 2021; 40(3):155-160. PubMed ID: 33749633
[TBL] [Abstract][Full Text] [Related]
40. Predictors of residual invasive disease after core needle biopsy diagnosis of ductal carcinoma in situ.
Rutstein LA; Johnson RR; Poller WR; Dabbs D; Groblewski J; Rakitt T; Tsung A; Kirchner T; Sumkin J; Keenan D; Soran A; Ahrendt G; Falk JS
Breast J; 2007; 13(3):251-7. PubMed ID: 17461899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
